Mark J. Mulvihill
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Mark J. Mulvihill has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
Alan C. Rigby
HiberCell Inc. 619 West 54th Street, New York, NY 10019, USA
1 shared publication- Alan C. Rigby
HiberCell Inc., 619 West 54th Street, New York, NY 10019, USA
1 shared publication - An-Hu Li
HiberCell Inc. 619 West 54th Street, New York, NY 10019, USA
1 shared publication - An-Hu Li
HiberCell Inc., 619 West 54th Street, New York, NY 10019, USA
1 shared publication Basanagoud S. Patil
AMRI, Plot #9, MN Park, Turkapally, Shameerpet, Genome Valley, RR District, Hyderabad 500078, India
1 shared publicationBhaskar Reddy Nareddy
AMRI, Plot #9, MN Park, Turkapally, Shameerpet, Genome Valley, RR District, Hyderabad 500078, India
1 shared publication
Latest Publications
- Open Access
- 19 October 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (10) , 2233
Optimization of a Novel Mandelamide-Derived Pyrrolopyrimidine Series of PERK Inhibitors
The protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is one of three endoplasmic reticulum (ER) transmembrane sensors of the unfolded protein response (UPR) responsible for regulating protein synthesis and alleviating ER stress. PERK has been implicated in tumorigenesis, cancer cell survival as well metabolic diseases such as diabetes. The structure-based design and optimization of a novel mandelamide-derived pyrrolopyrimidine series of PERK inhibitors as described herein, resulted in the identification of compound 26, a potent, selective, and orally bioavailable compound suitable for interrogating PERK pathway biology in vitro and in vivo, with pharmacokinetics suitable for once-a-day oral dosing in mice.
- 19 October 2022
- Published by MDPI AG in Pharmaceutics
- Vol. 14 (10) , 2233
Open AccessOptimization of a Novel Mandelamide-Derived Pyrrolopyrimidine Series of PERK Inhibitors
The protein kinase R (PKR)-like endoplasmic reticulum kinase (PERK) is one of three endoplasmic reticulum (ER) transmembrane sensors of the unfolded protein response (UPR) responsible for regulating protein synthesis and alleviating ER stress. PERK has been implicated in tumorigenesis, cancer cell survival as well metabolic diseases such as diabetes. The structure-based design and optimization of a novel mandelamide-derived pyrrolopyrimidine series of PERK inhibitors as described herein, resulted in the identification of compound 26, a potent, selective, and orally bioavailable compound suitable for interrogating PERK pathway biology in vitro and in vivo, with pharmacokinetics suitable for once-a-day oral dosing in mice.
- Open Access
- 1 July 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 43, 128058
Discovery of 2-amino-3-amido-5-aryl-pyridines as highly potent, orally bioavailable, and efficacious PERK kinase inhibitors
- 1 July 2021
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 43, 128058
Open AccessDiscovery of 2-amino-3-amido-5-aryl-pyridines as highly potent, orally bioavailable, and efficacious PERK kinase inhibitors